Background Over the last decade, biologics have gained an important place for the
treatment of moderate to severe inflammatory bowel disease (IBD), and many randomized …

Inflammatory bowel disease, including its 2 entities ulcerative colitis and Crohn's disease, is
a chronic medical condition characterized by the destructive inflammation of the intestinal …

In the last decade, biologic agents, in particular anti-TNF agents such as infliximab,
adalimumab, and certolizumab have substantially extended the therapeutic armamentarium …

Six biologic agents are currently approved for the treatment of IBD: four anti-TNF agents
(infliximab, adalimumab, golimumab and certolizumab pegol) and two anti-integrin agents …

Biologics have revolutionized the therapeutic approach in inflammatory bowel disease
(IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently …

Various novel drugs have recently been evaluated in clinical trials showing promising effects
in patients with inflammatory bowel disease (IBD). Here, we summarize the recent literature …

The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care.
Nonetheless, not all patients require biological therapy. Selection of patients depends on …

The pharmacological management of inflammatory bowel disease (IBD) over the last two
decades has transitioned from reliance on aminosalycilates, corticosteroids and …

INTRODUCTION Biologic therapies include:(1) naturally occurring or modified biologic
compounds such as vaccines (live, live attenuated, or killed microorganisms), hormone …

Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the
gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative …